Ankylosing Spondylitis PBMC
Powered by BiozAbout:Ankylosing Spondylitis PBMC from clinically confirmed donors, cryopreserved in CryoStor® CS10 within 24 hours of collection. Suitable for Th17 and IL-17 studies, gamma-delta T cell and MAIT cell characterisation, IL-23/IL-17 axis target validation, and HLA-B27-stratified comparative immunology in this seronegative immune-mediated disease.
About Ankylosing Spondylitis PBMC
Ankylosing Spondylitis PBMC for Immune-Mediated Inflammatory Disease Research
Ankylosing Spondylitis PBMC are isolated from the peripheral blood of IRB-consented donors with a clinically confirmed diagnosis of ankylosing spondylitis, cryopreserved in CryoStor® CS10 and processed within 24 hours of collection. These peripheral blood mononuclear cells give direct access to the lymphocyte populations that define this disease’s immunology, including the Th17 and innate-like T cell compartments.
HLA-B27 and the IL-23/IL-17 Axis
Ankylosing spondylitis is a seronegative immune-mediated inflammatory disease of the axial skeleton, characterised by sacroiliitis, spinal inflammation, enthesitis and pathological new bone formation. It is seronegative in the meaningful sense: there is no disease-defining autoantibody, and the immunology is dominated by genetic HLA association and a cytokine axis rather than by humoral autoimmunity.
- HLA-B27 is the strongest genetic association in ankylosing spondylitis and one of the strongest single-allele associations known in complex disease, though most carriers never develop the condition.
- The IL-23/IL-17 axis is the central effector pathway; the clinical efficacy of IL-17 inhibitors, and of TNF inhibitors, anchors this pathway in validated therapeutic mechanism rather than speculation.
- ERAP1 is a well-replicated susceptibility gene that interacts genetically with HLA-B27, linking antigen peptide trimming to disease risk.
- Th17 cells and IL-17-producing innate-like lymphocytes — including gamma-delta T cells, MAIT cells and group 3 innate lymphoid cells — are enriched or altered in spondyloarthritis and are all resolvable from a PBMC preparation.
- Enthesitis and new bone formation at sites of inflammation distinguish this disease from erosive rheumatoid arthritis, and the immune drivers of that anabolic bone response remain an active question.
- Extra-articular manifestations — acute anterior uveitis, inflammatory bowel disease and psoriasis — cluster with ankylosing spondylitis and support shared-pathway research across the spondyloarthritis spectrum.
Donor Stratification Available
- HLA-B27 status where documented
- Disease activity where documented, including elevated CRP or ESR
- Radiographic ankylosing spondylitis vs non-radiographic axial spondyloarthritis
- Treatment status: NSAID, conventional DMARD, TNF inhibitor, IL-17 inhibitor, JAK inhibitor, or treatment-naive
- Extra-articular involvement: uveitis, inflammatory bowel disease, or psoriasis
- Peripheral arthritis or enthesitis involvement
- Disease duration and age at symptom onset
- Matched healthy controls available
Product Features
- Research Use Only (RUO), cryopreserved PBMCs
- Clinically confirmed ankylosing spondylitis donors
- Available in cell counts ranging from 5 million to 2 billion
- Processed within 24 hours of collection
- Stored using CryoStor® CS10 freezing media
- Viability and recovery reported per lot
- IRB-approved protocols and electronic informed consent
- Screen LeukoLot™ available prior to bulk orders
De-identified Donor Data
- Verified ankylosing spondylitis diagnosis and diagnostic criteria applied
- Donor demographics: age, sex assigned at birth, race/ethnicity
- Treatment history, current regimen and disease activity where documented
- Self-reported allergies and infectious disease history
- Additional ankylosing spondylitis-specific data available upon request
Applications
- Th17 cell frequency, differentiation and IL-17 production assays
- Gamma-delta T cell, MAIT cell and innate lymphoid cell characterisation
- IL-23/IL-17 axis pathway analysis and target validation
- Immunophenotyping of T, B, NK and monocyte populations
- HLA-B27-stratified comparative immune studies
- Single-cell RNA sequencing and TCR repertoire analysis
- Pharmacodynamic profiling of TNF, IL-17 and JAK inhibitor effects on immune cells
- Biomarker discovery for disease activity and treatment response
Other Ankylosing Spondylitis Specimen Types
- Ankylosing Spondylitis Plasma
- Ankylosing Spondylitis Bulk Plasma
- Ankylosing Spondylitis Serum
- Ankylosing Spondylitis Whole Blood
- Ankylosing Spondylitis Leukopak
- Ankylosing Spondylitis Synovial Fluid
- Axial Spondyloarthritis Whole Blood
Compliance and Quality Assurance
- IRB-approved collections and protocols
- 21 CFR Part 11-compliant e-consent system
- HIPAA-compliant donor data protection
- Documentation support available for regulatory review
Ordering & Customization
Ankylosing Spondylitis PBMC samples are shipped on dry ice and available in custom aliquots. For pricing, current availability, international orders or regulatory documentation, contact learnmore@sanguinebio.com. To browse disease-state options and live stock status across our full PBMC inventory, visit our human PBMC page.
Applications
- Immunology and translational research
- Biomarker discovery and validation
- Drug screening and assay development
- Vaccine and infectious disease research
Product Features
- Research Use Only (RUO), PBMC
- Sourced from screened, consented donors
- Processed under validated SOPs
- QC tested for purity, viability, and sterility
- Processed within 24 hours of collection
- IRB-approved protocols with electronic informed consent
Donor Metadata
- Verified diagnosis and clinical history
- Demographic data: age, sex assigned at birth, race/ethnicity
- Medication and treatment background when available
Compliance and Quality Assurance
- IRB-approved collections and standardized procedures
- 21 CFR Part 11-compliant e-consent system
- HIPAA-compliant data management
Ordering & Customization
Human PBMC are available in customizable aliquot sizes. For international orders or documentation needs, please contact learnmore@sanguinebio.com to confirm requirements and availability. We also work with multiple ordering platforms and distributors, learn more here.
Protocols & Documentation
-
Download
PBMC Isolation from Whole Blood
Standard operating procedure for isolating peripheral blood mononuclear cells from whole blood using density-gradient separation.
-
Download
Immune Cell Isolation
Guidelines for isolating immune cell populations with validated enrichment steps, purity checkpoints, and documentation.
-
Download
Choosing the Right PBMC Configuration
Reference guide comparing PBMC formats, cryopreservation states, and study-fit recommendations for your application.
-
Download
Thawing Cryopreserved PBMC
Validated thawing protocol to recover viable cryopreserved PBMCs while minimizing activation and loss of function.
-
Informed Consent Form (ICF)
Available upon request — confirms donor consent for research use and downstream commercialization.
PBMC
Where can I find your complete catalog?
You can find our full product catalog here.
How long can samples be stored?
Storage depends on sample type but often cryopreserved samples stored in liquid nitrogen can be stored for years.
What customization options are available?
Extensive customization is available. To discuss your project request a quote or email us at learnmore@sanguinebio.com.
Do you offer prospective collections?
Sanguine offers flexible prospective collection services tailored to fit your research. For more information and to request a quote, please see: our prospective biospecimen collection services page.
What is the turnaround time for custom collections?
Timelines depend on condition, sample type, and I/E criteria but we often start collection within 2 weeks of signed agreement.
Do you have samples in stock?
YES - we have in-stock inventory. You can also email us at learnmore@sanguinebio.com as we continually get new samples in our inventory.
What does unique donor mean?
Each sample from a different individual - Unique donor means each sample comes from a different person, ensuring biological diversity in your study.
Are samples collected under IRB-approved protocols?
YES - "IRB-approved collection protocols" and IRB approval documentation available upon request. Sanguine utilizes two internationally-recognized IRBs (Advarra and WCG IRB) for review and approval.
Frequently Asked Questions
Ask a Question
Pair with a Healthy Control
Match your Ankylosing Spondylitis PBMC with normal donor samples for comparison
Healthy Donor PBMCs
705 In Stock View InventoryNeed a custom PBMC cohort?
Our scientific team can scope prospective collections with donor-specific I/E criteria, typically starting within 2 weeks of agreement.